SFXN5 and urogenital neoplasm: For prostatitis, TRMU and SFXN5 were identified as tier 3 genes, with TRMU emerging as a risk gene [eQTLGen: OR (95% CI) = 1.67 (1.29, 2.15), P-value = 8.96 × 10−5], and SFXN5 as a protective factor [eQTLGen: OR (95% CI) = 0.89 (0.80, 0.98), P-value = 0.02].